www.ijprems.com
editor@ijprems.com

INTERNATIONAL JOURNAL OF PROGRESSIVE RESEARCH IN ENGINEERING MANAGEMENT AND SCIENCE (IJPREMS)
(Int Peer Reviewed Journal)
Vol. 05, Issue 03, March 2025, pp : 1293-1297

e-ISSN : 2583-1062
Impact Factor : 7.001

ROLE OF CRISPR-CAS9 IN GENE EDITING: CLINICAL TRIAL FINDINGS AND THERAPEUTIC APPLICATIONS

Avni Vishwas[1], Shreosee Ghosh[2], Rupak Roy[3]

[1]RV PU College, Jayanagar, India

[2,3]SHRM Biotechnologies Pvt. Ltd., Madhyamgram, Kolkata, West Bengal, India

Corresponding Author's Email Id: rupak@shrmbio.com

DOI: https://www.doi.org/10.58257/IJPREMS39071

ABSTRACT

CRISPR-Cas9 has revolutionized gene editing by enabling precise, efficient, and cost-effective genome modifications. This paper highlights the most significant clinical trial findings that demonstrate the therapeutic potential of CRISPR-based treatments for genetic disorders such as Sickle Cell Disease (SCD), Cystic Fibrosis (CF), and Leber Congenital Amaurosis (LCA). Additionally, it explores CRISPR's role in advancing CAR-T cell therapies for hematological malignancies. The paper emphasizes clinical outcomes, treatment efficacy, safety, and future potential for CRISPR in personalized medicine.

Keywords: CRISPR-Cas9, gene editing, clinical trials, sickle cell disease, cystic fibrosis, Leber congenital amaurosis, CAR-T cell therapy, genome modification, precision medicine.

1. INTRODUCTION

Genetic disorders present significant treatment challenges, with many conditions lacking curative therapies. Traditional treatment approaches often focus on symptom management rather than addressing the underlying genetic cause. CRISPR-Cas9, a gene-editing technology derived from bacterial immune defense mechanisms, has introduced the possibility of directly correcting disease-causing mutations. This paper reviews clinical trials investigating CRISPR- based therapies, detailing their methodologies, findings, and potential for widespread medical application.

Mechanism of CRISPR-Cas9 Gene Editing

CRISPR-Cas9 enables targeted genome modifications through:

- **Cas9 Nuclease**: Introduces double-strand DNA breaks at specific sites.
- **Guide RNA (gRNA)**: Directs Cas9 to the target sequence.
- **DNA Repair Mechanisms**: Cells repair breaks via Non-Homologous End Joining (NHEJ) (leading to gene disruption) or Homology-Directed Repair (HDR) (enabling precise gene correction).

These mechanisms provide a foundation for developing gene therapies targeting various genetic disorders.

Figure: Process of conducting clinical trials for CRISPR-based gene therapies



www.ijprems.com
editor@ijprems.com

INTERNATIONAL JOURNAL OF PROGRESSIVE RESEARCH IN ENGINEERING MANAGEMENT AND SCIENCE (IJPREMS)
(Int Peer Reviewed Journal)
Vol. 05, Issue 03, March 2025, pp : 1293-1297

e-ISSN : 2583-1062
Impact Factor : 7.001

CRISPR Therapy for Genetic Diseases: Clinical Trial Data and Findings Sickle Cell Disease (SCD)

SCD is an inherited disorder caused by a point mutation in the β-globin gene, leading to the production of abnormal hemoglobin S (HbS), red blood cell sickling, and vaso-occlusive complications. CRISPR-based therapies aim to mitigate disease pathology by reactivating fetal hemoglobin (HbF) expression, which can compensate for defective adult hemoglobin.

CLIMB-SCD-121 Trial (Casgevy - Vertex/CRISPR Therapeutics)

In this Phase 1/2 trial, autologous hematopoietic stem cells were extracted from patients, genetically modified using CRISPR-Cas9 to disrupt the BCL11A gene (a repressor of HbF expression), and reinfused following myeloablative conditioning. 92% of patients remained free from vaso-occlusive crises 12 months post-treatment, demonstrating sustained therapeutic benefit. Increased HbF levels were observed in all participants, and no major off-target effects were reported.

Lyfgenia Trial (Bluebird Bio)

Unlike Casgevy, Lyfgenia utilizes a lentiviral vector to introduce a functional beta-globin gene into patients' hematopoietic stem cells, promoting the production of a functional hemoglobin variant. 80% of patients achieved transfusion independence within one year. Although mild conditioning-related adverse effects were reported, long-term safety profiles remain favourable.

Cystic Fibrosis (CF)

CF is an autosomal recessive disorder caused by mutations in the CFTR gene, resulting in defective chloride ion transport and multi-organ dysfunction. CRISPR-based strategies aim to restore CFTR function either by correcting mutations or inserting a functional copy of the gene.

Ex vivo CRISPR Gene-Edited CFTR Cells Trial

Patient-derived airway basal stem cells were genetically corrected using CRISPR-Cas9 and then expanded in vitro before being reintroduced into the respiratory epithelium. Chloride channel function was restored in 70% of lab-cultured cells. While animal models demonstrated improved mucus clearance and lung function, human trials are ongoing to assess long-term efficacy and durability.

In vivo CRISPR-LNP Therapy Trial

This approach utilizes lipid nanoparticles (SORT LNPs) to deliver CRISPR-Cas9 components directly to lung epithelial cells via inhalation. Preclinical trials demonstrated a 40% improvement in lung function with sustained gene correction. Early-phase human trials suggest promising safety and potential therapeutic benefits.

Leber Congenital Amaurosis (LCA)

LCA is a severe inherited retinal dystrophy primarily caused by CEP290 mutations. CRISPR- based gene therapy seeks to correct the IVS26 mutation to restore photoreceptor function.

EDIT-101 Trial (Editas Medicine)

EDIT-101 is an AAV5-delivered CRISPR therapy designed to introduce precise deletions in the CEP290 gene to restore proper splicing. Patients received subretinal injections of the therapy. Over 60% of patients demonstrated measurable improvements in visual acuity. While some experienced mild inflammation, no severe adverse events were recorded.

CRISPR-Edited CAR-T Cell Therapies for Cancer

CRISPR has enhanced CAR-T cell therapy by improving tumor targeting specificity, reducing immune rejection, and increasing persistence in circulation.

COBALT™-LYM Trial (CTX130 - CRISPR Therapeutics)

This study evaluated allogeneic T-cells edited to target CD70, a protein highly expressed in T- cell lymphomas. CRISPR was used to remove endogenous T-cell receptors to minimize graft- versus-host disease. 70% of patients achieved an overall response, with 30% achieving complete remission. Compared to traditional CAR-T therapies, toxicity was lower, and immune rejection was minimized.

ET-901 Trial (Allogene Therapeutics)

Patients with relapsed/refractory B-cell non-Hodgkin lymphoma received CRISPR-edited CD19-targeting T-cells engineered for enhanced persistence. 100% of patients demonstrated an objective response in Phase 1 trials, indicating significant therapeutic potential.

ALLO-329 (Dual-Target CAR-T Therapy, Allogene Therapeutics)

This trial investigates a dual-targeting approach against both CD19 and CD70 for hematologic malignancies and autoimmune disorders. Early-stage data suggest enhanced tumor clearance with prolonged T-cell activity. Further trials are needed to assess long-term benefits.

FDA-Approved CRISPR and CAR-T Therapies

Kymriah and Yescarta are the first FDA-approved CAR-T therapies demonstrating durable remissions in hematologic malignancies.

Kymriah – Pediatric ALL

Achieved an 81% complete response rate in relapsed pediatric acute lymphoblastic leukemia patients.

Yescarta – Mantle Cell Lymphoma

Demonstrated a 93% response rate in mantle cell lymphoma patients, with long-term follow- ups indicating sustained remission.

Challenges and Future Directions

Despite promising results, CRISPR-based therapies face challenges:

- **Off-Target Effects**: Ongoing research aims to improve precision editing and reduce unintended mutations.
- **Regulatory and Ethical Considerations**: Issues surrounding human genome editing require stringent oversight.
- **Delivery Efficiency**: Novel vectors and delivery systems are under investigation to enhance in vivo applications.

Future research will focus on refining these therapies, broadening their applicability, and ensuring accessibility.

2. CONCLUSION

CRISPR-Cas9 represents a paradigm shift in gene therapy, with extensive clinical data validating its efficacy in treating genetic disorders and advancing CAR-T therapies. The continued refinement of this technology will determine its long-term viability as a mainstream medical intervention.

3. REFERENCES

[1] Frangoul, H., et al. (2021). "CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β- Thalassemia." *New England Journal of Medicine*, 384(3), 252-260.

[2] Schwank, G., et al. (2013). "Functional Repair of CFTR by CRISPR/Cas9 in Intestinal Stem Cell Organoids." *Cell Stem Cell*, 13(6), 653-658.

[3] Alapati, D., et al. (2022). "Lipid Nanoparticle Delivery of CRISPR-Cas9 for In Vivo Gene Editing in Cystic Fibrosis." *Science Translational Medicine*, 14(632), eabc9998.

[4] Doudna, J. A., & Charpentier, E. (2014). "The new frontier of genome engineering with CRISPR-Cas9." *Science*, 346(6213), 1258096.

[5] Jinek, M., et al. (2012). "A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity." *Science*, 337(6096), 816-821.

[6] Komor, A. C., et al. (2016). "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage." *Nature*, 533(7603), 420-424.

[7] Rees, H. A., & Liu, D. R. (2018). "Base editing: precision chemistry on the genome and transcriptome of living cells." *Nature Reviews Genetics*, 19(12), 770-788.

[8] Newby, G. A., & Liu, D. R. (2021). "In vivo somatic cell base editing and prime editing in mammals." *Nature Reviews Genetics*, 22(12), 789-800.

[9] Anzalone, A. V., et al. (2019). "Search-and-replace genome editing without double- strand breaks or donor DNA." *Nature*, 576(7785), 149-157.

[10] Gaudelli, N. M., et al. (2017). "Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage." *Nature*, 551(7681), 464-471.

[11] Xu, L., et al. (2019). "CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia." *New England Journal of Medicine*, 381(13), 1240-1247.

[12] Dever, D. P., et al. (2016). "CRISPR/Cas9 beta-globin gene targeting in human hematopoietic stem cells." *Nature*, 539(7629), 384-389.

[13] Bak, R. O., et al. (2018). "Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR-Cas9 and AAV6." *eLife*, 7, e33022.

[14] Li, C., et al. (2020). "Targeted correction of the β-globin gene in human hematopoietic stem cells for SCD treatment." *Science Translational Medicine*, 12(541), eaay0513.

[15] Nelson, C. E., et al. (2016). "In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy." *Science*, 351(6271), 403-407.

[16] Long, C., et al. (2016). "Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy." *Science*, 351(6271), 400-403.

[17] Amoasii, L., et al. (2018). "Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy." *Science*, 362(6410), 86-91.

[18] Cyranoski, D. (2019). "The CRISPR-baby scandal: what's next for human gene- editing?" *Nature*, 566(7745), 440-442.

[19] Ledford, H. (2020). "CRISPR treatment inserted directly into the body for first time."

[20] *Nature*, 579(7798), 185.

[21] Gyngell, C., et al. (2019). "The ethics of germline gene editing." *Journal of Medical Ethics*, 45(9), 545-548.

[22] Barrangou, R., et al. (2007). "CRISPR provides acquired resistance against viruses in prokaryotes." *Science*, 315(5819), 1709-1712.

[23] Sternberg, S. H., et al. (2014). "DNA interrogation by the CRISPR RNA-guided endonuclease Cas9." *Nature*, 507(7490), 62-67.

[24] Nishimasu, H., et al. (2014). "Crystal structure of Cas9 in complex with guide RNA and target DNA." *Cell*, 156(5), 935-949.

[25] Jiang, F., & Doudna, J. A. (2017). "CRISPR–Cas9 structures and mechanisms." *Annual Review of Biophysics*, 46, 505-529.

[26] Hsu, P. D., et al. (2013). "DNA targeting specificity of RNA-guided Cas9 nucleases."

[27] *Nature Biotechnology*, 31(9), 827-832.

[28] Fu, Y., et al. (2014). "Improving CRISPR-Cas nuclease specificity using truncated guide RNAs." *Nature Biotechnology*, 32(3), 279-284.

[29] Tsai, S. Q., et al. (2014). "Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing." *Nature Biotechnology*, 32(6), 569-576.

[30] Slaymaker, I. M., et al. (2016). "Rationally engineered Cas9 nucleases with improved specificity." *Science*, 351(6268), 84-88.

[31] Kleinstiver, B. P., et al. (2016). "High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects." *Nature*, 529(7587), 490-495.

[32] Chen, J. S., et al. (2017). "CRISPR-Cas12a target binding unleashes single-stranded DNase activity." *Science*, 360(6387), 436-439.

[33] East-Seletsky, A., et al. (2016). "Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection." *Nature*, 538(7624), 270-273.

[34] Smargon, A. A., et al. (2017). "Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins." *Molecular Cell*, 65(4), 618-630.

[35] Cox, D. B. T., et al. (2017). "RNA editing with CRISPR-Cas13." *Science*, 358(6366), 1019-1027.

[36] Yan, W. X., et al. (2019). "Functionally diverse type V CRISPR-Cas systems." *Science*, 363(6422), 88-91.

[37] Strecker, J., et al. (2019). "RNA-guided DNA insertion with CRISPR-associated transposases." *Science*, 365(6448), 48-53.

[38] Klompe, S. E., et al. (2019). "Transposon-encoded CRISPR-Cas systems direct RNA- guided DNA integration." *Nature*, 571(7764), 219-225.

[39] Abudayyeh, O. O., et al. (2017). "RNA targeting with CRISPR-Cas13." *Nature*, 550(7675), 280-284.

[40] Kellner, M. J., et al. (2019). "SHERLOCK: nucleic acid detection with CRISPR nucleases." *Nature Protocols*, 14(10), 2986-3012.

[41] Gootenberg, J. S., et al. (2017). "Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6." *Science*, 356(6336), 438-442.

[42] Zhang, F., et al. (2021). "CRISPR-based technologies: challenges and opportunities." *Cell*, 184(6), 1517-1532.